Skip to main content
. 2023 Feb 6;24(4):e55069. doi: 10.15252/embr.202255069

Figure EV1. TRPV2 is dispensable for melanoma tumor cell proliferation (relative to Fig 3).

Figure EV1

  1. Representative proliferation curves comparing the effect of TRPV2 overexpression in 501mel cells, or TRPV2 repression in WM266.4 and 451Lu cells, measured by MTT at 12, 24, 48, or 72 h. Each data point represents the mean ± SEM of n = 3 biological replicates with two‐way ANOVA multiple comparisons test results for the 72 h time points (**P = 0.0038 for 501mel GFP vs. 501mel GFP‐TRPV2; ns P = 0.8422 for WM266.4 shRNA ctrl vs. ShRNA V2‐1, ns P = 0.9491 for WM266.4 shRNA ctrl vs. ShRNA V2‐2, ns P = 0.9982 for 451Lu shRNA ctrl vs. ShRNA V2‐1, ns P = 0.5755 for 451Lu shRNA ctrl vs. ShRNA V2‐2).
  2. Immunoblotting (IB) of TRPV2, Thr202/Tyr204 Phospho‐p44/42 MAPK (pERK), and the β‐actin as a loading control in melanoma cell lines modified for TRPV2 expression.

Source data are available online for this figure.